CancerDrs

Cervical Cancer clinical trials in Nebraska

15 actively recruiting cervical cancer trials at 9 sites across Nebraska.

Data from ClinicalTrials.gov · last refreshed

Phase 2, Phase 3 Recruiting NIH

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins i…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01810913
Sites in Nebraska:
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Nebraska Methodist Hospital — Omaha, Nebraska
  • Alegent Health Bergan Mercy Medical Center — Omaha, Nebraska
Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Nebraska:
  • NHO Revive Research Institute, LLC — Lincoln, Nebraska
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Nebraska:
  • Nebraska Medicine-Bellevue — Bellevue, Nebraska
  • Nebraska Medicine-Village Pointe — Omaha, Nebraska
  • University of Nebraska Medical Center — Omaha, Nebraska
Phase 2 Recruiting NIH

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from wh…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05904080
Sites in Nebraska:
  • Nebraska Cancer Specialists/Oncology Hematology West PC - MECC — Omaha, Nebraska
  • Nebraska Methodist Hospital — Omaha, Nebraska
  • Oncology Associates PC — Omaha, Nebraska
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Nebraska:
  • Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
  • University of Nebraska Medical Center — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…

Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Nebraska:
  • Nebraska Cancer Specialists — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Nebraska:
  • Nebraska Cancer Specialists — Omaha, Nebraska
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Nebraska:
  • Exelixis Clinical Site #2 — Omaha, Nebraska
  • Exelixis Clinical Site #5 — Omaha, Nebraska
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Nebraska:
  • CHI Health Saint Francis — Grand Island, Nebraska
  • Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
  • Alegent Health Immanuel Medical Center — Omaha, Nebraska
NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Nebraska:
  • CHI Health Saint Francis — Grand Island, Nebraska
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Alegent Health Immanuel Medical Center — Omaha, Nebraska
  • Alegent Health Bergan Mercy Medical Center — Omaha, Nebraska
  • Alegent Health Lakeside Hospital — Omaha, Nebraska
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Nebraska:
  • Massive Bio SYNERGY-AI site — Omaha, Nebraska
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Nebraska:
  • Mary Lanning Healthcare, Morrison Cancer Center — Hastings, Nebraska
  • Faith Regional Health Services, Carson Cancer Center — Norfolk, Nebraska
  • Great Plains Regional Medical Center — North Platte, Nebraska
  • Methodist Estabrook Cancer Center — Omaha, Nebraska
  • Nebraska Methodist Health System — Omaha, Nebraska
NA Recruiting Industry

Comprehensive Outcomes for After Cancer Health

This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer di…

Sponsor: Pack Health
NCT ID: NCT05349227
Sites in Nebraska:
  • University of Nebraska Medical Center — Omaha, Nebraska

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15